文献速递母胎医学产科

靶向二代测序在先天性心脏病胎儿中的临床应用

Clinical application of targeted next-generation sequencing in fetuses with congenital heart defect.
PubMed 文献 · Ultrasound Obstet Gynecol · 2018-06-25

研究对44例染色体核型正常且微阵列阴性的先天性心脏病胎儿行靶向二代测序,检出致病性变异13.6%(6/44)、可能致病性变异2.3%(1/44),检测周转时间3周,意义不明变异占79.5%。

要点

  • 靶向二代测序在先天性心脏病胎儿中检出致病性变异13.6%(6/44)。
  • 可能致病性变异检出率为2.3%(1/44),检测周转时间3周。
  • 意义不明变异在79.5%的病例中被检出。

核心结论

  • 靶向二代测序在孤立性和非孤立性先天性心脏病胎儿中在本队列中取得了高诊断率,周转时间适合产前场景。
  • 研究结果对临床管理和遗传咨询具有重要意义。

研究设计与样本

  • 44例先天性心脏病胎儿,染色体核型正常且染色体微阵列结果阴性,接受靶向二代测序。
  • 从每例产前病例的羊水细胞中直接提取胎儿基因组DNA。
  • 定制77个先天性心脏病相关基因的靶向二代测序panel,检测这些基因编码区及剪接位点的变异。
  • 检测到的变异按美国医学遗传学与基因组学学会推荐的指南分类为致病性、可能致病性、意义不明、可能良性或良性。

主要发现

  • 靶向二代测序对致病性变异的检出率为13.6%(6/44),对可能致病性变异的检出率为2.3%(1/44)。
  • 检测周转时间为3周。
  • 6个致病性变异分别位于CHD7(CHARGE综合征)、CITED2(法洛四联症、室间隔缺损和房间隔缺损)、ZFPM2(法洛四联症)、MYH6(房间隔缺损、家族性孤立性扩张型心肌病)及2例KMT2D(Kabuki综合征)。
  • 可能致病性变异位于JAG1,与法洛四联症和Alagille综合征相关。
  • 对胎儿及其父母的Sanger测序表明所有7个突变均为新发。

临床怎么用

  • 作者认为,靶向二代测序在孤立性和非孤立性先天性心脏病胎儿中取得了高诊断率,周转时间适合产前场景,对临床管理和遗传咨询具有重要意义。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the value of targeted next-generation sequencing (NGS) in prenatal diagnosis of congenital heart defects (CHD) and to investigate the genetic etiology of prenatal CHD. METHODS: Forty-four fetuses with CHD, normal molecular karyotype and negative chromosomal microarray results underwent targeted NGS. Fetal genomic DNA was extracted directly from amniotic fluid cells in each prenatal case. A customized targeted-NGS panel of 77 CHD-associated genes was designed to detect variants in the coding regions and the splicing sites of these genes. The detected variants were classified as pathogenic, likely pathogenic, of uncertain significance, likely benign or benign, following the guidelines recommended by the American College of Medical Genetics and Genomics. RESULTS: The detection rates of targeted NGS for pathogenic and likely pathogenic variations were 13.6% (6/44) and 2.3% (1/44), respectively. The turnaround time of the test was 3 weeks. The six pathogenic variations were identified on the genes CHD7 (CHARGE syndrome), CITED2 (tetralogy of Fallot, ventricular septal defect and atrial septal defect), ZFPM2 (tetralogy of Fallot), MYH6 (atrial septal defect, familial isolated dilated cardiomyopathy) and, in two cases, KMT2D (Kabuki syndrome). The likely pathogenic variation was detected on JAG1, which is associated with tetralogy of Fallot and Alagille syndrome. Sanger sequencing in the fetuses and their parents indicated that all seven mutations were de novo. Variations of uncertain significance were detected in 79.5% of cases. CONCLUSIONS: Targeted NGS in fetuses with isolated and non-isolated CHD achieved a high diagnostic yield in our cohort, with an acceptable turnaround time for the prenatal setting. Our results have important implications for clinical management and genetic counseling. Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Hu P, Qiao F, Wang Y, et al. Clinical application of targeted next-generation sequencing in fetuses with congenital heart defect. Ultrasound Obstet Gynecol. 2018. PMID: 29536580. doi:10.1002/uog.19042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。